Mostrar el registro sencillo del ítem

dc.contributor.authorMateos-Hernandez, Lourdes
dc.contributor.authorVillar, Margarita
dc.contributor.authorDoncel-Perez, Ernesto
dc.contributor.authorTrevisan-Herraz, Marco 
dc.contributor.authorGarcia-Forcada, Angel
dc.contributor.authorRomero Ganuza, Francisco
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorde la Fuente, Jose
dc.date.accessioned2017-10-20T10:33:51Z
dc.date.available2017-10-20T10:33:51Z
dc.date.issued2016
dc.identifierISI:000389632800014
dc.identifier.citationOncotarget. 2016; 7(46):74582-74591
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/20.500.12105/5175
dc.description.abstractGuillain-Barre syndrome (GBS) is an autoimmune-mediated peripheral neuropathy of unknown cause. However, about a quarter of GBS patients have suffered a recent bacterial or viral infection, and axonal forms of the disease are especially common in these patients. Proteomics is a good methodological approach for the discovery of disease biomarkers. Until recently, most proteomics studies of GBS and other neurodegenerative diseases have focused on the analysis of the cerebrospinal fluid (CSF). However, serum represents an attractive alternative to CSF because it is easier to sample and has potential for biomarker discovery. The goal of this research was the identification of serum biomarkers associated with recovery from GBS. To address this objective, a quantitative proteomics approach was used to characterize differences in the serum proteome between a GBS patient and her healthy identical twin in order to lessen variations due to differences in genetic background, and with additional serum samples collected from unrelated GBS (N = 3) and Spinal Cord Injury (SCI) (N = 3) patients with similar medications. Proteomics results were then validated by ELISA using sera from additional GBS patients (N = 5) and healthy individuals (N = 3). All GBS and SCI patients were recovering from the acute phase of the disease. The results showed that Piccolo, a protein that is essential in the maintenance of active zone structure, constitutes a potential serological correlate of recovery from GBS. These results provided the first evidence for the Piccolo's putative role in GBS, suggesting a candidate target for developing a serological marker of disease recovery.
dc.description.sponsorshipThis work was partially supported by EU FP7 ANTIGONE project number 278976. LMH was supported by a fellowship from the University of Castilla La Mancha (UCLM), Spain. MV was supported by the Research Plan of UCLM, Spain.
dc.language.isoeng
dc.publisherImpact Journals 
dc.type.hasVersionVoR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectNeuropathy
dc.subjectProteomics
dc.subjectBiomarker
dc.subjectGuillain-Barre
dc.subjectNeurology
dc.subjectImmunology and Microbiology Section
dc.subjectImmune response
dc.subjectImmunity
dc.subjectIMMUNE-MEDIATED NEUROPATHIES
dc.subjectCEREBROSPINAL-FLUID
dc.subjectMULTIPLE-SCLEROSIS
dc.subjectPERIPHERAL NEUROPATHIES
dc.subjectPEPTIDE IDENTIFICATION
dc.subjectMOLECULAR MIMICRY
dc.subjectMASS-SPECTROMETRY
dc.subjectSYNDROME GBS
dc.subjectANTIGANGLIOSIDE
dc.subjectCELLS
dc.titleQuantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barre syndrome
dc.typejournal article
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID27776345
dc.format.volume7
dc.format.page74582-74591
dc.identifier.doi10.18632/oncotarget.12789
dc.contributor.funderEuropean Commission 
dc.contributor.funderUniversity of Castilla-La Mancha (España) 
dc.description.peerreviewed
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.12789
dc.identifier.journalOncotarget
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovascular
dc.repisalud.institucionCNIC
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/278976es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional